(SERDs); fulvestrant; everolimus; compounds that block dihydroxy-testosterone production; 5α- and 5β-reductase inhibitors; abitraterone; trastuzumab; chemotherapeutic compounds; docetaxel; taxol derivatives; gemcitibine; bisphosphonates; pamidronate; and zoledronic acid.

15. The method of claim 9, wherein the patient has been diagnosed with either prostate cancer or breast cancer, and the established cancer cell line is a prostate or cancer cell line.

16. The method of claim 9, further comprising monitoring levels of at least one cancer specific biomarker and/or the levels of at least one marker of immune health in the patient.

17. The method of claim 9, wherein the immune cells are isolated from a biological sample selected from the group consisting of: blood; and lymph node tissue.

18. A method of treating a cancer in a patient, the method comprising administrating an anti-cancer therapy to the patient, wherein the candidate anti-cancer therapy comprises an immune cell activating agent and an antigen display enhancing agent that is able to stimulate or enhance the presentation of a cancer-specific antigen on the surface of cancer cells, and wherein the efficacy of the anti-cancer therapy is determined according to the method of claim 1.

(SERDs); fulvestrant; everolimus; compounds that block dihydroxy-testosterone production; 5α- and 5β-reductase inhibitors; abitraterone; trastuzumab; chemotherapeutic compounds; docetaxel; taxol derivatives; gemcitibine; bisphosphonates; pamidronate; and zoledronic acid.

15. The method of claim 9, wherein the patient has been diagnosed with either prostate cancer or breast cancer, and the established cancer cell line is a prostate or cancer cell line.

16. The method of claim 9, further comprising monitoring levels of at least one cancer specific biomarker and/or the levels of at least one marker of immune health in the patient.

17. The method of claim 9, wherein the immune cells are isolated from a biological sample selected from the group consisting of: blood; and lymph node tissue.

18. An anti-cancer therapy for use in the treatment of a cancer in a patient, wherein the candidate anti-cancer therapy comprises an immune cell activating agent and an antigen display enhancing agent that is able to stimulate or enhance the presentation of a cancer-specific antigen on the surface of cancer cells, and wherein the efficacy of the anti-cancer therapy is determined according to the method of claim 1.